PACE-CME

The role of ALP as predictor of CV events and vascular calcification in CKD

The role of ALP as predictor of CV events and vascular calcification in CKD
RestartResume
10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD
  • Overview

    Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.

  • Educational information

    This lecture by dr. Mathias Haarhaus, was part of an accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.

  • Faculty

    Dr. Mathias Haarhaus, MD, Consultant Nephrologist at the Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free